NCT06280157View on ClinicalTrials.gov

A Follow up Study of Group B Streptococcus (GBS)-NN/NN2 Vaccine in Healthy Volunteers

Enrolling by invitationOBSERVATIONAL
Enrollment

55

Participants

Timeline

Start Date

January 18, 2024

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Group B Streptococcus Infection
Interventions
BIOLOGICAL

GBS-NN/NN2

GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2

Trial Locations (1)

Unknown

Simbec-Orion Clinical Pharmacology, Merthyr Tydfil

Sponsors

Lead Sponsor

Minervax ApS

Collaborators (1)

Simbec-Orion Group
All Listed Sponsors
collaborator

Simbec-Orion Group

INDUSTRY

lead

Minervax ApS

OTHER

NCT06280157 - A Follow up Study of Group B Streptococcus (GBS)-NN/NN2 Vaccine in Healthy Volunteers | Biotech Hunter | Biotech Hunter